In both comparisons of AML patients with FLT-ITD mutation and CBF-AML with the control group, the most distinguishing compounds were found within sphingolipid and glycerophospholipid metabolism (Supplementary Fig. 8A and B). The gene discussed is CEBPZ; the disease is acute myeloid leukemia.